SPOTIFY
1.2.2021 23:03:12 CET | Business Wire | Press release
Today Spotify (NYSE: SPOT) launches its service in South Korea, giving Korean listeners access to over 60 million tracks and over 4 billion playlists from around the world. As the world’s most popular audio streaming subscription service, Spotify offers an effortlessly simple interface, an innovative technology framework, everyday new music discovery and algorithmic recommendations personalized to each listener’s music taste. This launch brings Spotify’s total number of markets to 93.
As the sixth-largest music market in the world*, South Korea is a critical next step in Spotify’s global expansion journey. Not only is South Korea among the most digitally inclusive markets in the world, but it is also widely recognized as a cultural and music epicenter, in part due to the global phenomena K-Pop. Since Spotify debuted its first K-Pop playlist in 2014, the share of K-Pop listening on the platform has increased by more than 2,000%. With this launch, Spotify plans to accelerate the growth of Korea’s entire music streaming ecosystem, benefitting creators, labels, distributors and fans.
“We always want to be where the listeners and artists are, and Korea is rich in both,” said Alex Norström, Chief Freemium Business Officer of Spotify. “This launch presents a massive opportunity for us to not only further our mission of bringing new and quality content to more audiences, but also help local Korean artists tap into Spotify’s 320 million listeners worldwide. We hope to create more opportunities for Korean artists across all genres to be discovered by listeners around the world.”
Spotify has uniquely tailored the music experience for each market. As a part of today’s launch, Spotify is introducing a range of new playlists made exclusively for South Korea. These playlists offer curated and the latest music from our team of Korean music experts, across some of the most popular genres. These include:
- TOP Playlists: Korean Music Hot Now , FRESH! New Music Korea , Hot Hits Korea , Korean Music Rising , Today's Drama OST Hot Now , K-Pop Daebak and more
- Genre Playlists : TrenChill K-R&B , TrenChill K-Hip Hop , K-HIP-HOP +82 , K-Are & Be , In The K-Indie , Korean City Pop , K-Rock Spirit , Folk & Acoustic Hot Now , Orchestra Korean Ballad and more
- Thematic Playlists : You Did Well , The End of the Day , So Cool Driving , Brain Rest 432Hz , Lullaby zZZ , Transcendental Game Play , Running K-Pop , GAYO Instrumentals , Spring Music , Into the Rain , Next Page of the Break-up , Kitchen Melodies and more
- ‘Starring’ playlists : This Is BTS , This Is BLACKPINK , This Is Stray Kids , This Is NCT , This Is TWICE , This is Taeyeon , This Is JAY Park , This Is CHUNG HA , This Is Loco and more
These new playlists will join Spotify’s K-Pop genre hub that encompasses a wide range of Korean music, including K-pop, Hip Hop, Indie, OST, R&B and more, as well as ‘RADAR Korea’, a playlist uncovering fresh K-music finds and a part of Spotify’s global emerging artist program. The hub is localized in over 72 countries, including Russia, India, Brazil and the UAE.
In Korea, new listeners can try out Spotify Premium 7 days-free on their mobile phone with no credit card information and a total of 3 months-free with credit card information, if subscribed before the end of June 2021. Listeners can engage with Spotify across a wide range of devices and app integrations including Instagram, Facebook, Samsung mobile and TV, LG TV, Microsoft Xbox, Bose and more.
The Spotify app is available to download for both Premium Individual and Duo plans. To enjoy music the way you want it, download the Spotify app today via the Android or iOS app store or by heading to www.spotify.com/kr-ko/ .
Click here for further imagery.
* According to IFPI (https://www.ifpi.org/wp-content/uploads/2020/07/Global_Music_Report-the_Industry_in_2019-en.pdf )
About Spotify Technology S.A.
Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators.
Today, with over 60 million tracks and over 4 billion playlists, we are the world’s most popular audio streaming subscription service with a community of more than 320 million listeners across 93 markets.
We use our Investors and For the Record websites as well as other social media listed in the “Resources – Social Media” tab of our Investors website to disclose material company information. For more information, images, or to contact the press team, head over to https://newsroom.spotify.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom